AbbVie: Rinvoq Meets Key Endpoints in Phase 3 Crohn's Disease Study

By Colin Kellaher

AbbVie Inc. on Monday said its Rinvoq immunology drug met the key endpoints in a Phase 3 induction study in patients with the inflammatory bowel disorder Crohn's disease.

The North Chicago, Ill., biopharmaceutical company said Rinvoq achieved both primary endpoints of clinical remission and endoscopic response at week 12 in the study, which enrolled patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy.

AbbVie said the trial is the first of a pair of Phase 3 induction studies to evaluate the safety and efficacy of Rinvoq in adults with moderate to severe Crohn's disease. AbbVie is studying the JAK inhibitor in several other immune-mediated inflammatory diseases.

Rinvoq is approved in the U.S. for adults with moderately to severely active rheumatoid arthritis and in Europe in indications in atopic dermatitis, active rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

December 06, 2021 09:05 ET (14:05 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.